Peter Altevogt focuses on Cell biology, Microvesicles, Cancer research, Molecular biology and Exosome. His research in Cell biology intersects with topics in Ectodomain, Integrin and Cell adhesion, Neural cell adhesion molecule. His study on Extracellular vesicle is often connected to Data sharing as part of broader study in Microvesicles.
His studies in Cancer research integrate themes in fields like Ovarian carcinoma, Metastasis, Cytotoxicity, Tumor progression and CD24. His Molecular biology study incorporates themes from Antigen, Matrigel, Cell adhesion molecule, Protease-activated receptor and Western blot. His studies deal with areas such as Vesicle, ADAM17 Protein, Endosome and ExoCarta as well as Exosome.
His scientific interests lie mostly in Cancer research, Molecular biology, Cell biology, Pathology and Antigen. His Cancer research research integrates issues from Cancer, Ovarian carcinoma, Ovarian cancer, Metastasis and Tumor progression. His research integrates issues of Epitope, Antibody and In vitro, Biochemistry in his study of Molecular biology.
The Cell biology study combines topics in areas such as Microvesicles and Cell, Integrin, Cell adhesion. He interconnects Carcinogenesis, Breast cancer, Pancreatic cancer and L1 in the investigation of issues within Pathology. His biological study spans a wide range of topics, including Phenotype, CD24 and Cytotoxic T cell.
The scientist’s investigation covers issues in Cancer research, Pathology, Cancer, Carcinoma and Molecular biology. His Cancer research research incorporates themes from Tumor progression and Metastasis. His work deals with themes such as Whole blood, Breast cancer, Factor XII and L1, which intersect with Pathology.
His work carried out in the field of Cancer brings together such families of science as Wnt signaling pathway, Growth inhibition and Immunology. His Molecular biology research includes themes of Transgene, Antibody, Monoclonal antibody and Cell biology. His Cell biology research is multidisciplinary, relying on both Cre recombinase, Messenger RNA, Lymphokine-activated killer cell and Extracellular vesicle.
His primary areas of study are Melanoma, Cancer research, Cell biology, Molecular biology and Microvesicles. Peter Altevogt combines subjects such as Natural killer T cell, Natural killer cell, Ectodomain, Disintegrin and Lymphokine-activated killer cell with his study of Melanoma. Peter Altevogt has included themes like Transforming growth factor, Carcinogenesis, Growth inhibition, Tumor progression and Lung cancer in his Cancer research study.
His Cell biology study combines topics from a wide range of disciplines, such as Cell, Immunoediting, Extracellular vesicle, Cre recombinase and Messenger RNA. His Molecular biology research incorporates elements of Metastasis and Transgene. His biological study focuses on Exosome.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Exosomes: from biogenesis and secretion to biological function.
Sascha Keller;Michael P. Sanderson;Alexander Stoeck;Alexander Stoeck;Peter Altevogt.
Immunology Letters (2006)
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation
Hina Kalra;Richard J. Simpson;Hong Ji;Elena Aikawa.
PLOS Biology (2012)
Body fluid derived exosomes as a novel template for clinical diagnostics
Sascha Keller;Johannes Ridinger;Anne-Kathleen Rupp;Johannes W G Janssen.
Journal of Translational Medicine (2011)
Interaction and uptake of exosomes by ovarian cancer cells
Cristina Escrevente;Sascha Keller;Peter Altevogt;Júlia Costa.
BMC Cancer (2011)
Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins
Sabine Mechtersheimer;Paul Gutwein;Nancy Agmon-Levin;Alexander Stoeck.
Journal of Cell Biology (2001)
L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers
Nancy Gavert;Maralice Conacci-Sorrell;Daniela Gast;Annette Schneider.
Journal of Cell Biology (2005)
CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells
Silke Aigner;Zev M. Sthoeger;Mina Fogel;Erich Weber.
Blood (1997)
L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.
Mina Fogel;Paul Gutwein;Sabine Mechtersheimer;Svenja Riedle.
The Lancet (2003)
CD24 Expression Is a New Prognostic Marker in Breast Cancer
Glen Kristiansen;Klaus-Jürgen Winzer;Empar Mayordomo;Joachim Bellach.
Clinical Cancer Research (2003)
CD24 mediates rolling of breast carcinoma cells on P-selectin
Silke Aigner;Carroll L. Ramos;Ali Hafezi‐Moghadam;Michael B. Lawrence.
The FASEB Journal (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
German Cancer Research Center
German Cancer Research Center
German Cancer Research Center
University Hospital Bonn
Rutgers, The State University of New Jersey
German Cancer Research Center
RWTH Aachen University
University of Miami
German Cancer Research Center
Goethe University Frankfurt
Apple (United States)
University of California, Berkeley
Indiana University
Rice University
MIT
Grenoble Alpes University
Academia Sinica
University of Ferrara
Pennsylvania State University
Peking University
North Carolina State University
National University of Singapore
Columbia University
University of Erlangen-Nuremberg
University of Cambridge
University of Oxford